First Trust Capital Management L.P.

CHICAGO, IL · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 6, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.08B2026 Q3
Positions185
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.58.3%

First Trust Capital Management L.P. reported 185 positions worth $2.08B as of September 30, 2026 (13F filed November 6, 2026). Largest holding: SPCX (25.7%). Biggest move: new buy SPCX ($533.1M).

10 / 185 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 SPCXSpace Exploration Technologies$533.1M25.67%3,533,950——-8.9%
▸ 2 WBDWarner Bros. Discovery$138.2M6.66%4,465,957——0.0%
▸ 3 ATKRAtkore$126.3M6.08%1,333,296——+0.2%
▸ 4 CZRCaesars Entertainment$81.7M3.93%2,754,430——-0.9%
▸ 5 CBZCbiz$74.3M3.58%1,359,439——+0.5%
▸ 6 LXPLXP Industrial$65.6M3.16%1,076,244——+0.4%
▸ 7 ITGRInteger$64.2M3.09%508,487——+0.3%
▸ 8 BLFSBiolife Solutions$55.4M2.67%1,425,085——-0.6%
▸ 9 ACVAACV Auctions$35.9M1.73%3,438,759——+0.7%
▸ 10 BZHBeazer Homes USA$35.4M1.71%1,062,853——+0.4%

Pro Feature

The remaining 175 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does First Trust Capital Management L.P. hold as of Q3 2026?

First Trust Capital Management L.P. reported 185 positions worth $2.08B in its Q3 2026 13F filing. Largest positions: SPCX (25.7%), WBD (6.7%), ATKR (6.1%), CZR (3.9%) and CBZ (3.6%).

What did First Trust Capital Management L.P. buy in Q3 2026?

New positions: SPCX, WBD, ATKR, CBZ and LXP (60 in all). Added to: CZR, GIX, CAII, IGAC and ARTC (26 in all).

What did First Trust Capital Management L.P. sell in Q3 2026?

Reduced: RF ACQUISITION CORP II, IPFX, JENA, APXT and AIMEI HEALTH TECHNOLOGY CO L (7 in all). Sold out entirely: TMHC*, GTLSGBP, NUVLEUR, NSA* and APOGEE THERAPEUTICS INC (36 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.